Tarek Assi (T Assi)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 30

Top Topics

Locally Advanced

Acute Lymphoblastic Leukemia

Squamous Cell Carcinoma

Top Venues

Future oncology (London, England)

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Pharmacogenomics

This page only lists publications with an associated author ORCID identifier.

Publications

Tarek Assi, Zamzam Tikriti, Annoir Shayya, Rebecca Ibrahim
Targeting RET mutation in medullary thyroid cancer. Pharmacogenomics 25 (3) (2024)
Tarek Assi
Immune checkpoint inhibitors in follicular dendritic cell sarcoma. Immunotherapy (2024)
Tarek Assi, Zamzam Tikriti, Annoir Shayya, Rebecca Ibrahim
Targeting RET mutation in medullary thyroid cancer. Pharmacogenomics (2024)
Tarek Assi, Zamzam Tikriti, Annoir Shayya, Rebecca Ibrahim
Targeting RET mutation in medullary thyroid cancer. Pharmacogenomics 25 (3) (2024)
Tarek Assi
Immune checkpoint inhibitors in follicular dendritic cell sarcoma. Immunotherapy 16 (6) (2024)
Tarek Assi
Immune checkpoint inhibitors in follicular dendritic cell sarcoma. Immunotherapy 16 (6) (2024)
Tarek Assi, Axel Le Cesne
Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas? Immunotherapy 15 (1) (2023)
Tarek Assi, Axel Le Cesne
Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas? Immunotherapy 15 (1) (2023)
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Future oncology (London, England) 19 (9) (2023)
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Future oncology (London, England) 19 (9) (2023)
Tarek Assi, Rebecca Ibrahim, Toni Ibrahim, Rita Khoury, Axel Le Cesne
Ipilimumab and nivolumab: the 'new kid on the block' in advanced angiosarcoma. Immunotherapy (2023)
Rebecca Ibrahim, Rita Khoury, Tony Ibrahim, Tarek Assi, Axel Le Cesne
KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment. Future oncology (London, England) (2023)
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Future oncology (London, England) 19 (9) (2023)
Tarek Assi, Carine Ngo, Matthieu Faron, Benjamin Verret, Antonin Lévy, Charles Honoré, Clémence Hénon, Cécile Le Péchoux, Rastilav Bahleda, Axel Le Cesne
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review. Current treatment options in oncology (2023)
Tarek Assi, Axel Le Cesne
Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes? Future oncology (London, England) (2023)
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Future oncology (London, England) (2023)
Tarek Assi, Axel Le Cesne
Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas? Immunotherapy 15 (1) (2023)
Tarek Assi, Axel Le Cesne
Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas? Immunotherapy (2023)
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Future oncology (London, England) 19 (9) (2023)
Tarek Assi, Olivier Mir
Hyperprogressive disease in leiomyosarcoma: a threat to the use of single-agent anti-PD-(L)1 therapy? Immunotherapy 14 (5) (2022)
Tarek Assi
Is there a role for immune checkpoint inhibitors in chordoma? Immunotherapy 13 (12) (2021)
Joseph Kattan, Tarek Assi
COVID-19 pandemic shakes the trust between oncologists and their patients. International journal of clinical practice 75 (10) (2021)
Tarek Assi, Joseph Kattan, Ahmad Othman, Fadi Farhat
Immune checkpoints inhibitors in metastatic squamous cell carcinoma of the vulva. Future oncology (London, England) 17 (24) (2021)
Marc El Beaino, Daniel C Jupiter, Tarek Assi, Elie Rassy, Alexander J F Lazar, Dejka M Araujo, Patrick P Lin
Diagnostic Value of TLE1 in Synovial Sarcoma: A Systematic Review and Meta-Analysis. Sarcoma 2020 (2020)
Elie Rassy, Rita-Maria Khoury-Abboud, Nathalie Ibrahim, Tarek Assi, Bachar Samra, Colette Hanna, Fadi El Karak, Marwan Ghosn
Should we screen patients with hematologic malignancies for COVID-19? Hematological oncology 38 (5) (2020)
Tarek Assi, Axel Le Cesne, Olivier Mir
Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma? Immunotherapy 13 (2) (2020)
Tarek Assi, A Cavalcanti, A Le Cesne, M Faron, J F Honart, A Hadiji, O Camuzard, T Ibrahim, C LePéchoux, O Mir, S Dumont, P Terrier, J Adam, C Honoré
Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 21 (9) (2019)
Tarek Assi, E El Rassy, F Farhat, J Kattan
Overview on the role of preoperative therapy in the management of kidney cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 22 (1) (2019)
Ziad Bakouny, Tarek Assi, Elie El Rassy, Karen Daccache, Clarisse Kattan, Aline Tohme, Marie Claire Mouhawej, Joseph Kattan
Factors associated with the time to first palliative care consultation in Lebanese cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 27 (4) (2018)
E El Rassy, Tarek Assi, Z Bakouny, N Pavlidis, J Kattan
Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 21 (3) (2018)